FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases by Mojsilovic-Petrovic, Jelena et al.
Neurobiology of Disease
FOXO3a Is Broadly Neuroprotective In Vitro and In Vivo
against Insults Implicated in Motor Neuron Diseases
Jelena Mojsilovic-Petrovic,1Natalia Nedelsky,2Marco Boccitto,1 Itzhak Mano,3 Savvas N. Georgiades,4Weiguo Zhou,1
Yuhong Liu,5 Rachael L. Neve,6 J. Paul Taylor,2Monica Driscoll,3 Jon Clardy,4Diane Merry,5 and Robert G. Kalb1,2
1Department of Pediatrics, Division of Neurology, Abramson Research Center, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104,
2Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, 3Department of Molecular Biology and
Biochemistry, Nelson Biological Laboratories, Rutgers University, Piscataway, New Jersey 08854, 4Department of Biological Chemistry and Molecular
Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, 5Department of Biochemistry and Molecular Biology, Thomas Jefferson University,
Philadelphia, Pennsylvania 19107, and 6Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts 02178
Aging is a risk factor for the development of adult-onset neurodegenerative diseases. Although some of themolecular pathways regulat-
ing longevity and stress resistance in lower organisms are defined (i.e., those activating the transcriptional regulators DAF-16 andHSF-1
in Caenorhabditis elegans), their relevance to mammals and disease susceptibility are unknown. We studied the signaling controlled by
the mammalian homolog of DAF-16, FOXO3a, in model systems of motor neuron disease. Neuron death elicited in vitro by excitotoxic
insult or the expression of mutant SOD1, mutant p150glued, or polyQ-expanded androgen receptor was abrogated by expression of
nuclear-targeted FOXO3a. We identify a compound [Psammaplysene A (PA)] that increases nuclear localization of FOXO3a in vitro and
in vivo and show that PA also protects against these insults in vitro. Administration of PA to invertebratemodel systems of neurodegen-
eration similarly blocked neuron death in a DAF-16/FOXO3a-dependent manner. These results indicate that activation of the DAF-16/
FOXO3a pathway, genetically or pharmacologically, confers protection against the known causes of motor neuron diseases.
Introduction
Although motor neuron diseases attributable to single gene mu-
tations are unusual (10%of cases), the affected genes have been
successfully used tomodel these diseases in experimental systems
(Cleveland and Rothstein, 2001). Rare, genetic forms of motor
neuron disease that arise from mutations in superoxide dis-
mutase (SOD) or p150glued have a disease phenotype that
strongly resembles sporadic amyotrophic lateral sclerosis (ALS)
with lower motor neuron predominance (Pasinelli and Brown,
2006). Another predominantly lower motor neuron disease,
called spinobulbar muscular atrophy (SBMA) (or Kennedy’s dis-
ease) is attributable to a polyglutamine expansion in the andro-
gen receptor (AR) (La Spada et al., 1991). Despite identification
of the “disease protein,” the underlying pathogenic mecha-
nism(s) remain incompletely understood.
In most cases of sporadic ALS, motor neuron death is trig-
gered by the interaction of a genetic predisposition and environ-
mental factors (Bruijn et al., 2004). Genome-wide association
studies have failed to reveal consistent susceptibility loci (Dunck-
ley et al., 2007; Kasperaviciute et al., 2007). Correlative evidence
suggests that aging is a risk factor for the development of ALS as
well as other adult-onset neurodegenerative disorders (Lin and
Beal, 2006). Studies from a variety of experimental systems have
provided insight into the genetic factors controlling aging, in
particular, the insulin/insulin-like growth factor signaling path-
way (Hekimi and Guarente, 2003; Longo and Finch, 2003). In
Caenorhabditis elegans, hypomorphic alleles of the daf-2 gene
(mammalian homolog, insulin/insulin-like growth factor recep-
tor) and the downstream signaling molecule age-1 [mammalian
homolog, phosphotidylinositol-3-kinase (PI3K)] promote lon-
gevity and lifespan extension. These effects require the activity of
the DAF-16 transcription factor (mammalian homolog,
FOXO3a) (Tatar et al., 2003).
DAF-16/FOXO3a shuttles between the cytoplasm (in which it
is inactive) and the nucleus in a process that is controlled by its
phosphorylation state (Brunet et al., 1999). Phosphorylation of
DAF-16/FOXO3a by the PI3K substrate kinases Akt and serum/
glucocorticoid-regulated kinase (SGK) (Brunet et al., 2001) leads
to the 14-3-3 protein-dependent export of nuclear DAF-16/
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FOXO3a and reentry into the nucleus requires dephosphoryla-
tion and release of 14-3-3 (Brunet et al., 2001; Greer and Brunet,
2005).Within the nucleus, DAF-16/FOXO3a leads to the expres-
sion of a number of genes that have context-dependent effects on
cellular physiology. Expression of a constitutively nuclear
FOXO3a can promote the death of purified motor neurons and
cerebellar granule cells, and this has been linked to the expression
of FasL (Brunet et al., 1999; Barthe´le´my et al., 2004). In contrast,
active FOXO3a protects a variety of quiescent cells against death
evoked by oxidative stress or glucose deprivation, and this has
been linked to the expression of manganese superoxide dis-
mutase (MnSOD) and catalase (Kops et al., 2002; Nemoto and
Finkel, 2002). Thymocyte survival and differentiation is FOXO3a
dependent (Leenders et al., 2000). Differences in beneficial versus
harmful effects of FOXO3a probably relate to cell-circumstance-
specific level of activation and posttranslational modifications
(Birkenkamp and Coffer, 2003).
Some of the stresses that contribute to motor neuron death in
ALS include excitotoxicity, reactive oxygen species, accumula-
tion of insoluble aggregates of neurofilaments, and defects in
axonal transport (Cleveland and Rothstein, 2001; Rao andWeiss,
2004; Boille´e et al., 2006; Lobsiger and Cleveland, 2007). Because
DAF-16/FOXO3a-dependent gene transcription, in some con-
texts, combats cellular stresses, we inquired whether manipulat-
ing FOXO3a signaling protected neurons from insults relevant to
motor neuron diseases.We show that FOXO3a activation is neu-
roprotective across phyla and identify a toxicity-sparing pharma-
cological approach for enhancement of DAF-16/FOXO3a signal-
ing activation.
Materials andMethods
Source of reagents. Trophic factors [ciliary neuronotrophic factor
(CNTF), brain-derived neurotrophic factor (BDNF), neurotrophin 4
(NT-4), cardiotrophin 1 (CT-1) and glial-derived neurotrophic factor
(GDNF)] were obtained from Alomone Labs. Psammaplysene A (PA)
was synthesized as described previously (Georgiades and Clardy, 2005).
All other reagents were obtained from Sigma and were of the highest
grade available.
Tissue culture. Embryonic Sprague Dawley rat spinal cord neurons
were grown on confluent monolayers of cortical astrocytes, as described
previously (Hu and Kalb, 2003). The substratum was acid washed glass
coverslips when imagingwas performed andPrimaria tissue culture plas-
ticware (Falcon; BD Biosciences Discovery Labware) when biochemistry
was performed. Culturemedia consisted of astrocyte-conditionedmedia
supplemented with 10 ng/ml CNTF, BDNF, NT-4, CT-1, and GDNF,
and 50% of media was replaced with fresh media every 3 d.
Male SBMA mice transgenic for the prion protein promoter-driven
androgen receptor cDNA containing an expanded (112) CAG repeat
tract were mated with nontransgenic C57BL/6 female mice (Chevalier-
Larsen et al., 2004). Dissociated, mixed spinal cord cultures obtained
from 13.5-day-old embryos were grown for 3 weeks in conditioned me-
dium (conditioned on normal mouse astrocytes) containing charcoal-
stripped serum to remove hormones. At 3 weeks, motor neurons were
well differentiated and distinguishable from other neurons, including
sensory neurons, by size and morphology. At this time, cultures were
treated with indicated conditions for 7 d; cells were then fixed with 4%
paraformaldehyde and immunostained using antibodies to neurofila-
ment heavy chain (SMI32; Sternberger Monoclonals). Motor neurons
were visualized using a Leica DMR fluorescence microscope, photo-
graphed, and analyzed using IP Labs software. Statistical analyses of re-
sults were performed using Student’s t test (viral infections) or ANOVA
(compound treatments; SigmaStat).
Recombinant herpes simplex virus. cDNAs were cloned into the PrpUC
amplicon plasmid to generate recombinant herpes simplex virus (HSV)
as described previously (Neve et al., 1997). The titer of virus used in these
studies was routinely 3–5  107 plaque-forming units (pfu)/ml. The
sources of constructs were as follows: Michael Greenberg, Harvard Uni-
versity, Boston, MA [hemagglutinin (HA)-tagged wild-type (WT) and
triple-mutant (TM) human FOXO3a]; David Borchelt, University of
Florida, Gainesville, FL (WT and G85R mutant SOD); Erika Holzbaur,
University of Pennsylvania, Philadelphia, PA (WT and mutant
p150glued); and Dr. Anne Brunet, Stanford University, Stanford, CA [3x
fork head response element luciferase (3xFHRE-luciferase)].
Excitotoxicity assay. After 14 d in vitro (DIV), culture media was re-
moved (and saved), and cells were exposed to 100Mkainic acid (KA) for
1 h. Subsequently, they were washed three times in Locke’s buffer not
containing KA, and the original media were replaced and incubated for
another 24 h at 37°C in 5%CO2 before fixation in 4%paraformaldehyde.
Motor neurons were identified in mixed culture by immunostaining for
nonphosphorylated neurofilaments and counting only labeled cells with
cell body diameter of 25mor greater.We have previously validated this
method as a means of specifically recognizing motor neurons
(Mojsilovic-Petrovic et al., 2006, their Fig. 1). In experiments involving
recombinant HSV, 1l of viral stock was added to 1 ml of culture media
24 h or more before the next manipulation. Tubes containing viruses
were color coded so that the operator was blinded to the specific virus
used.
Quantification of motor neurons. The number of immunostained cells
were counted in three randomly selected fields per coverslip, and the
mean value was obtained. In each experiment, at least three independent
coverslips were used per condition, and the results presented were ob-
tained for at least four independent cultures and experiments.
Immunocytochemistry. Tissue culture cells were fixed in freshly pre-
pared 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, for 30
min before extensive washing in PBS. Overnight incubation with pri-
mary antibody was performed at room temperature, and, after washing,
coverslips were incubated with Alexa fluor-conjugated secondary anti-
body (2–4 h). When double-labeling experiments were performed,
species-specific secondary antibodies with distinct emission spectra were
used. Coverslips were washed before mounting in PermaFluor (Thermo
Fisher Scientific) and viewing on anOlympus FV300 Fluoview laser con-
focal microscope.
Western blots and quantification. Cultures were lysed in NP-40 lysis
buffer (1% NP-40, 40 mM Tris, pH 7.4, 0.15 M NaCl, 10% glycerol, 0,1%
SDS, 0.1% deoxycholate plus protease inhibitors and phosphatase inhib-
itors) and sonicated, and particulate matter was removed by centrifuga-
tion and subjected to SDS-PAGE before transfer to nitrocellose. Equal
amounts of protein (determined using BCA reagents from Pierce) were
loaded in each lane. After blocking in 5% milk in PBS, membranes were
incubated in primary antibody overnight, washed, incubated with
secondary antibody, washed, and visualized to GE Healthcare chemilu-
minescent substrate according to the directions of the manufacturer.
Densitometric analysis of films was obtained using TINA (Isotopen-
meßgera¨te) from at least four independent experiments, the results were
averaged, and the mean  SE values formed the basis of the statistical
comparisons. Quantitative data on band intensity was expressed as the
fold change compared with values of HSV–LacZ-infected cultures. The
displayed Western blot data are representative of the results obtained
from at least four independent cultures. In some experiments, the LI-
COR Biosciences Odysseus system was used for visualizing and quanti-
fyingWestern blot bands. Secondary antibodies were from LI-COR Bio-
sciences (IR 800 or 680 goat anti-mouse IgG or anti-rabbit IgG). The
source of primary antibodies was as follows: rabbit anti-MnSOD (Stress-
gen), rabbit anti- FKHRL1/FOXO3a and anti-phospho FKHRL1/
FOXO3a (T32) (Upstate), anti-phosphoFOXO3a (S253) (Abcam), and
rabbit anti-HA (Santa Cruz Biotechnology). Species-specific HRP-
conjugated secondary antibodies were from GE Healthcare, and Alexa
488-conjugated anti-rabbit secondary antibody was from Invitrogen.
Subcellular fractionation. Nuclear protein lysate was prepared using
SigmaN-Xtract Tmkit. Briefly, cells collected fromone 60mmdishwere
suspended in 150l of hypotonic lysis buffer (in mM: 10 HEPES, pH 7.9,
1.5 MgCl2, and 10 KCl). After incubating on ice for 10 min, 10% IGEPA
CA-630 was added to final concentration of 0.6%, vortexed vigorously
for 10 s, and centrifuged immediately at 10,000–11,000 g for 30 s. The
supernatantwas cytoplasmic fraction, and the pellet was nuclear fraction.
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Luciferase reporter assay. Human embryonic kidney 293 (HEK 293)
cells were grown to 80% confluence and then transfected with
3xFHRE-luciferase (FHRE), the parent vector lacking the FHREs
(pGL3), or pGL3 vector containing 3x retinoic acid response element
(3xRARE-luciferase) (Addgene). In all cases, the Renilla luciferase re-
porter construct, driven by the thymidine kinase promoter, was cotrans-
fected as an internal control for transfection efficiency and cell death.
After 24 h, the cells were trypsinized and replated into media containing
the appropriate concentration of PA or vehicle. After 48 h, the cells were
trypsinized again and replated into a 96-well plate in fresh media con-
taining PA or vehicle (12 replicates per condition). Twenty-four hours
later, the plates were analyzed using the Dual-Glo Luciferase Assay Sys-
tem (Promega) on the Xenogen In Vitro Imaging System. The ratio of
luciferase signal to Renilla signal for each well was calculated, and the
various treatment groups were compared with vehicle.
Bioinformatics. To identify genes that were differentially expressed in
ALS, we accessed the National Center for Biotechnology Information
(NCBI) Gene Expression Omnibus (GEO) database and searched the
available datasets for ALS-related microarray data. Five datasets were
identified, and these were analyzed using the two-tailed t test analysis
with a 0.050 significance level, as provided on the GEO site, to compare
the control group with the ALS group in each of the datasets. The data
from these differentially expressed genes were then downloaded into a
spreadsheet and searched for genes thatwere previously determined to be
controlled by FOXO (Ramaswamy et al., 2002). Genes that were present
in both lists were added to the supplemental table (available at www.
jneurosci.org as supplementalmaterial), and their direction of regulation
was indicated.
Study of mice. B6SJL-Tg(SOD1–G93A)1Gur/J mice were obtained
from The Jackson Laboratory and were bred to the F1 generation of
C57BL/6  SJL mice. The offspring of this cross was used for all of the
biochemical studies (n 4 in each experimental group). Lumbar spinal
cord was obtained at postnatal day 87, frozen on dry ice until use. The
spinal cord segments were homogenized with a Dounce in NP-40 buffer
as above (10:1 v/w). All othermanipulation of the lysateswas as described
for tissue culture cells.
Study ofDrosophila.Drosophila stocks were crossed on standard corn-
meal agarmedia at 29°C. Foodwas supplemented with DHT (Steraloids)
and Psammaplysene A once it had cooled to50°C, to final concentra-
tions of 1 and 0.5mM, respectively. Eye phenotypes of female flies of each
condition were examined and blindly scored according to the criteria
described with one scoring modification to increase sensitivity to differ-
ences in affected eye areas (Pandey et al., 2007).
Flies haploinsufficient forDrosophila FOXO (dFOXO)were generated
by mating GMR–GAL4, AR52Q flies to the following fly stock lines:
foxoBG01018 (Bloomington Stock Center stock 12530); foxo21, foxo25
(Ju¨nger et al., 2003), and foxoc01841 (Exelixis).
Study of C. elegans. The following C. elegans strains were obtained
from the C. elegans Genetic Center (biosci.umn.edu/CGC) or con-
structed by us: glt-3, ZB1096 glt-3(bz34) IV; nuIs5, KP742[glr-1::gfp;
glr-1::Gs(Q227L) V; lin-15(	)]; glt-3; nuIs5, ZB1102 glt-3(bz34) IV;
nuIs5 V. For age-1; glt-3; nuIs5, strain ZB1102 glt-3(bz34) IV; nuIs5 V
was crossed with strain BE13 sqt-1(sc13)II. sqt-1was then kicked out and
replaced by age-1 using strain TJ1052 age-1(hx546) II. For
Pmyo-3:daf-16::gfp, strain ZB2283 was produced by Jian Xue and Carolina
Ibanez-Ventoso (both fromRutgers University, Piscataway, NJ) bymak-
ing transgenic animals carrying an extrachromosomal array containing
Pmyo-3:daf-16:gfp.
For PA treatment, we soaked the diluted drug into standard nematode
growthmediumculture plates.We transferred freshly growing nematode
cultures to these plates and allowed them to grow for 2 d before assessing
the effect. To determine the ratio of nuclear versus cytoplasmic DAF-16
levels, we used a strain transgenic for Pmyo-3:daf-16::gfp, in which the
DAF-16::GFP reporter is expressed in body wall muscle cells. We com-
pared the intensity of green fluorescent protein (GFP) labeling in the
nucleus and adjacent cytoplasm using NIH Image. We monitored the
effect of PA or age-1 on nematode excitotoxicity bymeasuring the extent
of neurodegeneration inglt-3; nuIs5 animalswith orwithout PAorwith
or without age-1 mutation. We observed free-moving animals with an
inverted scope under Nomarski differential interference contrast optics
with no anesthetics. Swollen cells in the nerve-ring region were counted
as head necrotic figures indicative of neurodegeneration.
Statistics. Pairwise comparisons used two-tailed Student’s t test, and,
when three or more groups were compared, we used ANOVA and post
hoc analysis with significance set at p 0.05.
Results
In fibroblasts, expression of FOXO3a with alanine substitutions
at three phosphorylation sites [threonine 32 (T32), serine 253
(S253), and serine 315 (S315)] leads to nuclear retention of the
transcriptionally active protein (Brunet et al., 2001). Cultures of
rat spinal cord neurons were infected with recombinant HSV
engineered to express the TM orWT FOXO3a. Immunostaining
for the transgene demonstrated that theWTFOXO3a is restricted
to the neuronal cytoplasm and the TM FOXO3a is primarily
nuclear (Fig. 1A). The transgene products were detectable in all
neurons for 
5 d without any apparent toxicity. To determine
whether these transgenes influenced the susceptibility of motor
neurons to excitotoxic insult, 14 DIV mixed spinal cord cultures
were infected withHSV–WT-FOXO3a, HSV–TM-FOXO3a, HS-
V–LacZ, or no virus, the following day were exposed to an exci-
totoxic challenge (100MKA or vehicle for 1 h), and the number
of surviving motor neurons determined 24 h later (Fryer et al.,
1999, 2000). Although 45% of motor neurons were killed by
KA in theHSV–LacZ- andHSV–WT-FOXO3a-infected cultures,
no KA-induced motor neuron death occurred in the HSV–TM-
FOXO3a-infected cultures (Fig. 1B). ANOVA using transgene
expression as the between-group factor and survival as the
within-group factor demonstrated a significant difference be-
tween groups (F(5,12) 15.68; p 0.001, ANOVA). The post hoc
comparisons between groups using Scheffe´’s F test with signifi-
cance set at p 0.05 showed that significant motor neuron death
only occurred in the cultures expressing the WT FOXO3a or
LacZ. Thus, expression of the TM FOXO3a protects cultured
motor neurons from excitotoxic insult.
Next we explored the capacity of TM FOXO3a to protect mo-
tor neurons in vitro from a variety of proteotoxic insults relevant
to motor neuron diseases. In spinobulbar muscular atrophy, a
polyglutamine expansion in the AR leads to testosterone-
dependent motor neuron death (Chevalier-Larsen et al., 2004).
We made cultures from spinal cord of mutant AR-expressing
mice and found that a 7 d treatment with DHT led to the loss of
25% of motor neurons compared with the vehicle-treated cul-
tures ( p  0.05) (Fig. 1C). We observed an equivalent rate of
DHT-dependent motor neuron death in cultures treated with
HSV–WT-FOXO3a ( p 0.05). Infection of cultures with HSV–
TM-FOXO3a, however, completely blocked DHT-dependent
death of motor neurons, with all motor neurons surviving in the
presence of DHT (Fig. 1C).
Proteotoxic motor neuron death can also be precipitated by
expression of mutant forms of human superoxide dismutase or
p150glued (Mojsilovic-Petrovic et al., 2006). We asked whether
treating cultures expressing these mutant proteins with TM
FOXO3a affectedmotor neuron death.We began these studies by
determining concentrations of viruses that led to coexpression of
both transgenes in neurons but did not lead to toxicity because of
the viral burden. We established that infection of spinal cord
neurons with8 104 pfu of HSV-mutant SOD permilliliter of
culture media reliably induced 50% motor neuron loss 7 d after
infection. Addition of8 104 more pfu of HSV–LacZ to these
wells did not exacerbate motor neuron death. Immunocytologi-
cal localization studies revealed that 97 2% of motor neurons
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expressingmutant SOD also expressed-galactosidase (Fig. 1D).
In all subsequent studies, we confirmed a
95% coexpression of
the toxicity-inducing mutant protein (SOD or p150glued) and
LacZ or TM FOXO3a. We also established that coexpression of
LacZ with eitherWT SOD orWT p150glued had no adverse effect
on motor neuron survival. We have shown previously that this
concentration of HSV-mutant SOD infects all motor neurons at
this plating density (Hu and Kalb, 2003; Mojsilovic-Petrovic et
al., 2006).
We compared next the outcome of cultures infected with
HSV-mutant SODplusHSV–LacZ orHSV–TM-FOXO3a as well
as cultures infected with HSV-mutant p150glued plus HSV–LacZ
or HSV–TM-FOXO3a (Fig. 1E). The ANOVA indicates that sta-
tistically significant differences between groups existed (F(5,12)
70.14; p 0.0001). Infection of cultures with HSV-mutant SOD
plusHSV–LacZ led to significantly lowermotor neuron numbers
when compared with cultures infected with HSV-mutant SOD
plus HSV–TM-FOXO3a (35.0  4.0 vs
69.0  2.0; p  0.05 in post hoc analysis).
Similarly, motor neuron numbers from
cultures infected with HSV-mutant
p150glued plus HSV–LacZ were signifi-
cantly lower than motor neuron numbers
from cultures infected with mutant
p150glued plusHSV–TM-FOXO3a (36.0
4.0 vs 68.0 3.0; p 0.05 in post hoc anal-
ysis) (Fig. 1E). Thus, the toxicity of three
different mutant proteins that cause mo-
tor neuron disease can be blocked by ex-
pression of a version of FOXO3a that con-
stitutively resides in the nucleus.
Inhibition of PI3K should lead to ac-
cumulation of FOXO3a dephosphorylated
at T32, S253, and S315 and enhanced par-
titioning of FOXO3a into the nucleus.
Given this, we wondered whether PI3K
inhibition would confer neuroprotection.
We began these experiments by determin-
ing that application of the PI3K inhibitor
LY294002 [2-(4-morpholinyl)-8-phenyl-
1(4H)-benzopyran-4-one] (final concen-
tration, 20 M) every other day for 6 d did
not adversely affect motor neuron sur-
vival under our culture conditions (data
not shown). Next we examined the bio-
chemical effects of LY294002. For this
set of experiments, the culture media
was supplemented with CNTF, CT-1,
NT-4, and GDNF but lacked BDNF.
Neurons were pretreated with LY294002
or vehicle for 30 min before acute stim-
ulation with BDNF (50 ng/ml) or vehi-
cle, and then lysates were prepared 30
min later (Fig. 2A). In the absence of
LY294002, BDNF evoked an increase in
the phosphorylation of AKT, mitogen-
activated protein kinase (MAPK), and
T32 and S253 of FOXO3a. No changes in
the abundance of the nonphosphory-
lated species were noted. In cultures pre-
treated with LY294002, application of
BDNF evoked an increase in MAPK
phosphorylation, but there were no
changes in the phosphorylation of AKT and T32 and S253 of
FOXO3a. No changes in the abundance of the nonphosphory-
lated species were noted. These results suggest that LY294002
selectively inhibit the PI3K signaling pathway and phosphor-
ylation of FOXO3a. Next we investigated the effects of chronic
LY294002 application to cultures supplemented with all five of
the above trophic factors. Twenty-four hour incubation with
LY294002 compared with vehicle-treated cultures led to a de-
crease in the abundance of phospho-AKT and phosphoryla-
tion at the S253 site on FOXO3a (Fig. 2B). No other changes
were noted in the phosphorylated proteins studied, and no
changes were detected in the abundance of the nonphospho-
rylated species. Next we looked at the effects of 6 d incubation
with LY294002 (fresh drug applied every other day) (Fig. 2C).
We found that incubation with LY294002 compared with
vehicle-treated cultures led to a decrease in the abundance of
phosphor-AKT, phosphor-MAPK, and phosphorylation of
Figure 1. Triple-mutant FOXO3a is retained in the nucleus and protects against excitotoxic and proteotoxic insults. A, Mixed
spinal cord neuronswere transfected using Lipofectamine 2000 (Invitrogen)with HA-taggedWT FOXO3a or TM FOXO3a and, 24 h
later, were fixed and immunostainedwith anti-HA antibody and Alexa-488 conjugated secondary antibody. In the left frame,WT
FOXO3a is present in neurites and the soma cytoplasm, whereas the nucleus appears devoid of immunoreactivity. In the right
frame, TM FOXO3a is seen primarily concentrated in the nucleus while soma and neurite staining is weak. Scale bar, 24m. B,
Mixed spinal cord cultures were maintained for 14 DIV before infection with HSV–LacZ, HSV–WT-FOXO3a, or HSV–TM-FOXO3a.
Twenty-four hours later, the cultures underwent a 1 h excitotoxic insult, and, after 24 h, the cultures were fixed and stained for
SMI32. The number of SMI32	motor neurons surviving each treatment is noted on the ordinate axis. A statistically significant
reduction in motor neuron number is seen in all groups except the cultured treated with HSV–TM-FOXO3a. C, The 14 DIV mixed
spinal cord cultures from mice engineered to express polyQ expanded AR were infected with HSV–LacZ, HSV, WT FOXO3a, or
HSV–TM-FOXO3a and then treated with DHT or vehicle. After 7 d, fixed cultures were stained, and the number of motor neurons
survivingwas determined. A statistically significant, DHT-dependent deathwas found in the uninfected group and the HSV–WT-
FOXO (but not HSV–TM-FOXO3a) group. D, Cultures were infected with HSV-mutant SOD (green) and HSV–LacZ (red) and
subsequently stainedwith specific antibodies. A highdegree of colocalization is evident (yellow,merge image). Scale bar, 40m.
E, The number of motor neurons surviving each treatment was determined after infecting 14 DIV cultures with combinations of
HSV–LacZ, TM FOXO3a, mutant SOD, mutant p150 glued, WT SOD, or WT p150 glued. Mutant SOD and mutant p150 glued motor
neuron death is blocked when TM FOXO3a is expressed.
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T32 and S253 of FOXO3a. In summary, these experiments
indicate that inhibition of PI3K has the desired effect of de-
creasing the abundance of phosphorylated FOXO3a.
To determine whether LY294002 was neuroprotective, cul-
tures were infected with either WT or mutant SOD-expressing
viruses, and LY294002 or vehicle was added to the culture media
every other day for 6 d (Fig. 2D). In the presence of WT SOD,
equivalent levels of motor neuron survival was found in the pres-
ence or absence of LY294002. In addition, in the presence of
mutant SOD, equivalent levels of motor neuron death were
found in the presence or absence of LY294002. These results in-
dicate that LY294002 is not toxic on its own and does not protect
motor neurons from mutant SOD toxicity. Because LY294002
reduces FOXO3a phosphorylation but is not neuroprotective, it
may be that phosphorylation of other PI3K targets in mamma-
lian cells offset any potential beneficial actions of dephosphory-
lated FOXO3a.
A chemical-genetic screen recently reported the identification
of a series of compounds that can inhibit FOXO1a nuclear ex-
port. Compounds fell into two classes: (1) inhibitors of general
nuclear export machinery and (2) inhibitors specific to the
FOXO1a pathway (Kau et al., 2003). We inquired whether com-
pounds in the second class would also block the nuclear export of
FOXO3a because they would be predicted (based on the results
above) to display neuroprotective activity. We focused on PA,
whichwas isolated from amarine sponge, because it was themost
potent of the class 2 inhibitors (Fig. 3A) (Schroeder et al., 2005).
In addition, PAwas reported to have no effect onAKTphosphor-
ylation, suggesting that it acted either downstream of AKT or in a
synergistic pathway.
We began by looking at the effect of a synthetic sample of PA
(for synthesis, see Georgiades and Clardy, 2005) on the distribu-
tion of FOXO3a endogenously expressed by neurons. We bio-
chemically isolated nuclei from spinal cord cultures treated with
PA or vehicle (Fig. 3B). Based on the distribution of the nuclear
envelope protein lamin, it is clear that our subcellular fraction-
ation procedure greatly enriched nuclei. There was an2.5-fold
increase in the nuclear FOXO3a/nuclear lamin ratio in the PA-
treated cultures compared with vehicle-treated cultures. Total
FOXO3a and lamin levels were unaffected by drug treatment.
These observations indicate that PA promotes the sequestration
of FOXO3a into nuclei.
We next tested the ability of PA to promote FOXO-dependent
transcription.HEK293 cells were transfectedwith a plasmid con-
taining a minimal promoter containing 3xFHRE driving lucif-
erase expression and then treated with various concentrations of
PA or vehicle for 72 h. As a control for a nonspecific action of PA
on transcription, a parallel set of cells were transfected with the
parent plasmid (pGL3) that lacked the 3xFHRE. In all experi-
ments, an internal control plasmid expressing Renilla luciferase
was cotransfected, and all results are expressed as the ratio lucif-
erase/Renilla fluorescence. PA treatment led to a dose-dependent
increase in luciferase signal in 3xFHRE-expressing but not pGL3-
expressing cells (Fig. 3C). As an added control for specificity, we
looked at the ability of PA to enhance transcription from a
3xRARE luciferase construct and found that PA had no effect on
this promoter. These results indicate that PA can promote FOXO
transcriptional activity.
To determine whether PA had neuroprotective activity, spinal
cord cultures were treated with the drug (10 nM) for 2 d and then
subjected to an excitotoxic challenge (Fig. 3D). The percentage of
KA-induced cell death was 50% in vehicle-treated cultures
(65 2 vs 35 3 for vehicle vs KA; p 0.01, Student’s t test) and
3% in PA-treated cultures (67 3 vs 65 2 for vehicle vs KA;
p  0.6, Student’s t test), indicating that PA protected motor
neurons from excitotoxic challenge. Next we looked at mutant
AR proteotoxicity (Fig. 3D). Significant differences between
groups (F(2,6)  18.84, ANOVA) were found in the three-way
comparison of (1) no DHT, (2) DHT plus vehicle, and (3) DHT
plus PA). The post hoc analysis demonstrated a DHT-dependent
25% loss of motor neurons in vehicle-treated cultures ( p 
0.01) and neuroprotection in the PA-treated cultures ( p
 0.05
in the comparison of no DHT vs DHT plus PA).
We followed up these observations by asking whether PA
blocked the proteotoxicity of SOD or p150glued. Spinal cord cul-
tures were infected with HSV engineered to express the WT or
mutant forms of SOD or the WT or mutant forms of p150glued
and received PA (or vehicle) every other day for 4 d. The drug
treatment had no effect on transgene expression (data not
shown). After 4 d, the cultures were fixed, and motor neuron
number was determined. ANOVA revealed statistically signifi-
cant differences between groups in LacZ versus WT SOD versus
mutant SOD (with or without PA) comparisons (F(5,12) 18.41;
p  0.001) as well as LacZ versus WT p150glued versus mutant
Figure 2. Inhibition of PI3K reduces FOXO3a phosphorylation but does not protect against mutant SOD toxicity. Mixed spinal cord cultures were grown in the absence of BDNF and pretreated
with LY294002 or vehicle before acute stimulation with BDNF. Thirty minutes after application of BDNF, lysates were prepared for Western blot analysis. A shows that LY294002 blocks the BDNF
stimulated increase in phospho-AKT, phospho-MAPK, and phosphorylation of FOXO3a on T32 and S253. B shows the effect of a 24 h treatment with LY294002 of cultures chronically grown in five
trophic factors, includingBDNF.ByWesternblot analysis, LY294002 suppressesphospho-AKTandphosphorylationof FOXO3aonS253.C shows theeffect of a6d treatmentwith LY294002of cultures
chronically grown in five trophic factors, including BDNF. ByWestern blot analysis, LY294002 suppresses phospho-AKT, phospho-MAPK, and phosphorylation of FOXO3a on T32 and S253. D shows
the number ofmotor neurons surviving 6 d of infectionwith HSV–WT-SOD or HSV-mutant SOD grown in the presence or absence of chronic LY294002.Mutant SOD led to50%motor neuron loss,
and LY294002 did not abrogate the process.
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150glued (with or without PA) comparisons (F(5,12) 19.26; p
0.001) (Fig. 3E). The post hoc analysis revealed that statistically
significant protection against the toxicity of mutant SOD or
p150glued was conferred by PA treatment on motor neuron sur-
vival. PA had no adverse effect on survival of motor neurons
expressing LacZ or wild-type versions of SOD or p150glued. Thus,
PA is nontoxic on its own but can protect against four different
insults in vitro that are directly relevant tomotor neuron diseases.
Although the direct molecular target of PA is unknown, we
examined the effect of PA on some candidate biochemical and
cell biological processes that have been implicated previously in
neuron death. Neurotrophins (such as BDNF) can promote neu-
Figure 3. PA drives FOXO3a into the neuronal nucleus, promotes FOXO-dependent transcription, and protects against the proteotoxicity of mutant SOD and mutant p150 glued. A, The chemical
structureofPA.B, Subcellular fractionationof 14DIV spinal cord culture lysates treatedwithPAor vehicle.Nuclear fraction (enriched for thenuclearmarker lamin) containsmoreFOXO3a inPA-versus
vehicle-treated cultures. Theabundanceof total FOXO3a, lamin, or actin is the sameunderboth conditions.Quantificationofband intensities showthatPA treatment leads toa statistically significant
increase in nuclear FOXO3a/nuclear lamin comparedwith vehicle-treated cultures. C, PA promotes transcription from a 3xFHRE-luciferase reporter in a dose-dependentmanner. PA affected neither
transcription from the parent vector (pGL3 that lacks the FHREs) nor a 3xRARE-luciferase reporter. There was a statistically significant difference between vehicle treatment of 3xFHRE versus PA
concentrations 10 nM (*p 0.05), 50 nM (**p 0.01), and 100 nM (***p 0.001).D, Pretreatment of mixed spinal cord cultures with PA (	PA) protectedmotor neurons from excitotoxic insult
(left bar graph) andDHT-dependent death of polyQ expandedAR toxicity (right bar graph).E, One set of 14DIVmixed spinal cord cultureswas infectedwithHSV–LacZ, HSV–WT-SOD, orHSV-mutant
SOD, and a second set of cultures was infected with HSV–LacZ, HSV–WT-p150 glued, or HSV-mutant p150 glued. Survival of SMI32-stainedmotor neurons was determined 4 d later. Infected cultures
were either treated with vehicle (PA) or PA (	PA). Mutant SOD led to a statistically significant reduction in motor neuron number (by ANOVA; see Results for details), and this was prevented in
PA-treated cultures. Similarly, mutant p150 glued led to a statistically significant reduction in motor neuron number, and this was prevented in PA-treated cultures. *p 0.05.
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ronal survival by activating its receptor,
TrkB, both during development and after
insult (Koliatsos et al., 1993; Ernfors et al.,
1994; Klo¨cker et al., 1998) (but see Koh et
al., 1995; Mojsilovic-Petrovic et al., 2006),
and so we wondered whether PA had de-
monstrable effects on this signaling path-
way. Spinal cord cultures grown for 14
DIV were infected with HSV-mutant SOD
and then PA or vehicle was added to the
cultures. Under these conditions, in the
absence of BDNF, the level of active,
phosphor-Trk receptor is very low (Fig.
4A). Similarly, downstream signaling in-
volvingAKT andMAPK are onlymodestly
active. In response to BDNF addition to
the media, there is a rapid and robust acti-
vation of the Trk receptor (as monitored
by assaying for the phosphorylated formof
the receptor) aswell as phosphor-AKTand
phosphor-MAPK. The temporal pattern
of receptor activation and downstream
signaling in our cultures conforms to pre-
vious observations (Fryer et al., 2000; Hu
andKalb, 2003) (Fig. 4A). Identical results
were obtained in cultures uninfected with
viruses (data not shown). Thus, we find no
evidence that pretreatment of cultures
with PAhas any effect on themagnitude or
duration of BDNF–TrkB signaling.
Insoluble aggregates of mutant SOD
are detectable within cells from transgenic
mice engineered to express mutant SOD
(Bruijn et al., 1997;Watanabe et al., 2001).
We wondered whether WT or mutant
SOD aggregated in neurons in vitro and
whether treating cultures with PA influ-
enced the cellular distribution of human
transgene SOD. Immunocytological loca-
tion of human SOD in cultures infected
with HSV–WT-SOD revealed that the
protein is homogeneously distributed
throughout the cytoplasm and extends
centrifugally for
100 m into axons and
dendrites (Fig. 4B). In contrast, in cultures infected with HSV–
mutant SOD immunoreactivity is concentrated into puncta (the
cytological signature of insoluble aggregated proteins) in the
soma cytoplasm and neurites. Double-labeling studies reveal that
mutant SOD puncta are present in motor neurons (identified by
SMI32 immunoreactivity) as well as nonmotor neurons in our
cultures (Fig. 4B). Treatment of cultureswith PAhad no effect on
the subcellular distribution of human SOD in cultures infected
with either of the recombinant HSVs. Although the pathophysi-
ological significance of aggregated protein is controversial, these
results indicate that the neuroprotective action of PA is disso-
ciable from the accumulation of aggregated mutant SOD. A sim-
ilar observation has been made in C. elegans wherein DAF-16
protects against-amyloidA1–42 toxicity but does not influence
the accumulation of protein aggregates (Cohen et al., 2006).
Because the neuroprotection conferred by PA does not seem
to be linked to alterations in trophic factor signaling or the gen-
eration of macroscopic mutant SOD aggregates, perhaps PA ac-
tion is linked to its capacity to promote nuclear localization of
FOXO3a. This would be consistent with the observations that PA
causes nuclear partitioning of FOXO3a in neurons and constitu-
tive localization of FOXO3a in the nucleus is broadly neuropro-
tective. We began with biochemical studies of spinal cord neu-
rons in vitro expressingWT SOD or mutant SOD. In the absence
of PA, the abundance of phosphorylated FOXO3a at T32 (or its
ratio to the nonphosphorylated species) is the same in mutant
versusWT SOD-expressing cultures (Fig. 4C). The samewas true
when we assayed phosphorylation of S253 (data not shown).
Conversely, one transcriptional target of FOXO3a is MnSOD,
and the abundance of this protein is markedly depressed in mu-
tant SOD compared with WT SOD-expressing cultures. Expres-
sion of neithermutant norWTSOD led tomeasurable changes in
total FOXO3a or actin. In the presence of PA treatment, the
abundance of phosphorylated FOXO3a (or its ratio to the non-
phosphorylated species) is the same in mutant versus WT SOD-
expressing cultures (Fig. 4C). Interestingly, PA treatment rescued
the mutant SOD effect on the level of MnSOD such that MnSOD
abundance was equal in the mutant versus WT SOD-expressing
Figure4. Effects of PAon the distribution ofWTandmutant SOD in vitro andbiochemical consequences ofWTandmutant SOD
in vitro and in vivo. A, Mixed spinal cord cultures infected with HSV–WT-SOD or HSV–G87R–SODwere treated with PA or vehicle
overnight before stimulation with 50 ng/ml BDNF. Lysates of unstimulated cells or stimulated cells at the given time points were
subjected toWestern blot analysis. The kinetics and degree of TrkB pathway stimulation is the same in PA- versus vehicle-treated
cells. B, Mixed spinal cord cultures infected with HSV–WT-SOD or HSV–G85R–SODwere treated with PA or vehicle for 3 d before
fixation and immunostaining for human SOD. WT SOD is homogenously distributed throughout the cytoplasm in the neuronal
soma and processes in the absence of PA (PA) and in the presence of PA (	PA). In contrast, G87R–SOD assumes a punctate
patternof expression indicative of aggregates of theprotein inboth theabsenceof PA (PA) and thepresenceof PA (	PA). Scale
bar, 20m. Below, using cultures infected with HSV–G85R–SOD, motor neurons are stained with SMI32 (left) and anti-human
SOD (middle). Aggregatedmutant SOD is localized withinmotor neurons (yellow in right). Scale bar, 15m. C, In the absence of
PA (PA) treatment, spinal cord cultures expressingmutant SODorWTSODhave the sameabundanceof phosphor-FOXO3a (T32)
and the nonphosphorylated species. In addition, mutant SOD-expressing cultures have decreased abundance of MnSOD. In the
presence of PA (	PA), there is no difference in the abundance of phospho-FOXO3 or nonphosphorylated FOXO3a in cultures
expressingWT ormutant SOD. In addition, the level of expression of MnSOD is no longer suppressed bymutant SOD expression in
PA-treated cultures. D, Western blots of lumbar spinal cord lysates from two wild-type (labeled 1 and 2) and G93A mutant SOD
mice (labeled 1 and 2). Representative Western blots show an increase in the abundance of T32 phospho-FOXO3a in the lysates
from the mutant mice as well as a decrease in the abundance of MnSOD. Quantification of these results are shown in the
histograms below.
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cultures. PA had no effect on the abundance of total FOXO3a or
actin. These findings suggest that mutant SOD proteotoxic stress
in vitro is not associated with a change in the state of phosphor-
ylation of FOXO3a at sites that regulate its subcellular distribu-
tion. However, mutant SOD expression results in a reduction in
the abundance of a FOXO3a transcriptional target (MnSOD),
raising the possibility that proteotoxic stress might influence the
FOXO3a signaling pathway. How PA treatment reverses the mu-
tant SOD-dependent effect on MnSOD expression, and whether
it is linked to FOXO3a, will require additional study.
Given these in vitro observations, we wondered whether a
similar phenomenon occurs in mutant SODmice. We examined
lysates from spinal cords of mice expressing the G93A mutant
form of human SOD or wild-type controls for the expression of
phosphor-FOXO3a and target genes. The mice were 87 d old, a
time when they are asymptomatic in terms of weakness but do
manifest other subtle abnormalities
(Mourelatos et al., 1996; Frey et al., 2000;
Pun et al., 2006). A consistent increase in
the phosphorylation of T32 of FOXO3a
(and the ratio of phosphor-FOXO3a to the
nonphosphorylated species) was seen in
the G93A mice compared with the wild-
type animals (n  4 in each experimental
group) (Fig. 4D). This was associated with
a reduction in MnSOD in the G93A mice
compared with the wild-type animals. No
differenceswere noted in the abundance of
actin in the mutant versus wild-type ani-
mals. Thus, in both in vitro and in vivo
experiments, mutant SOD expression is
associated with a reduction in MnSOD ex-
pression. The effect of mutant SOD expres-
sion on FOXO3a phosphorylation differed
in the in vitro versus in vivo paradigms.
To further explore this issue, we used
bioinformatics tools to query existing mi-
croarray profiles for a potential connec-
tion between motor neuron disease and
FOXO3a-dependent transcription. We
identified five microarray datasets located
in the NCBI GEO server that are relevant
to motor neuron disease. These datasets
come from studies of postmortem tissue
from ALS patients and mutant SOD
mouse or rat tissues at various stages of
disease. To our knowledge, the only de-
scription of the FOXO3a transcriptome
comes from a study of phosphatase and
tensin homolog (PTEN) null 786-O renal
carcinoma cells (Ramaswamy et al., 2002).
This study identified 198 transcripts
whose level of expression is changed by at
least twofold when a DNA binding-
competent, constitutively nuclear (triple-
mutant) FOXO3a, is expressed in these
cells. When we asked how many genes in
themotor neuron disease dataset were also
components of the FOXO3a transcrip-
tome, we identified 22 transcripts in both
datasets (supplemental table, available at
www.jneurosci.org as supplemental mate-
rial). Even given the disparate experimen-
tal platforms used in these studies, the presence of any overlap-
ping dataset is intriguing. A better-controlled prospective study is
required to obtain a more full understanding of the potential
importance of FOXO3a in motor neuron disease pathogenesis.
In light of the neuroprotective effect of PA in vitro, we exam-
ined the effects of the drug in two in vivomodel systems of neu-
ronal degeneration. Expression of polyglutamine-expanded AR
in the Drosophila eye leads to DHT-dependent degeneration
(Takeyama et al., 2002; Pandey et al., 2007). We found that flies
reared on food supplemented with 0.5 mM PA had a reduced
degenerative phenotype when compared with vehicle-treated
flies (Fig. 5a,b). These in vivo results complement the observa-
tions made in spinal cord cultures from mice expressing
polyglutamine-expanded AR wherein we found expression of
TMFOXOor treatment with PA blunts DHT-dependentmutant
AR toxicity.
Figure 5. PA suppresses degeneration in a Drosophila model of SBMA in a dFOXO-dependent manner. Right panel of each
diptych shows highermagnification of the posteriormargin of the eye, inwhich degeneration is concentrated. a, Flies expressing
polyglutamine-expanded human androgen receptor (GMR, AR52Q) show degeneration when reared on food containing 1 mM
dihydrotestosterone (	DHT). b, This degeneration is suppressed when food is supplemented with 0.5 mM PA. c, d, PA fails to
rescue AR52Q-mediated degeneration in a dFOXO-deficient background. Bar graph below, Quantification of the degenerative eye
phenotype (scoredaccording toPandeyet al., 2007) shows that theneuroprotectiveeffect of PA is lostwhen flies arehaploinsufficient for
dFOXO.Numbersof eyes scoredareas follows:GMR,AR52:DMSO,n34,PA,n41;GMR,AR52; foxoBG01018:DMSO,n37,PA,n
47; GMR, AR52; foxo21: DMSO,n20, PA,n16; GMR, AR52; foxo 25: DMSO,n8, PA,n14; GMR, AR52; foxo C01841: DMSO,n
28, PA,n 20.Mean values are indicatedwith SE. p valuewas determinedusing Student’s t test. *p 0.05.
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We next asked whether the neuropro-
tective action of PA depended on FOXO.
To this end, we examined the efficacy of
PA in flies that both expressed the
polyglutamine-expanded AR and were
haploinsufficient for dFOXO (Fig. 5c,d).
In a dFOXO-deficient background (fox-
oBG01018 allele) (Dionne et al., 2006), PA
lost its ability to protect against DHT-
dependent degeneration. To corroborate
these observations, we studied two addi-
tional dFOXO loss-of-function alleles
(foxo21 and foxo25) and one predicted
loss-of function allele (foxoC01841) (Ju¨nger
et al., 2003; Thibault et al., 2004). As above,
on all of these dFOXO-deficient back-
grounds, PA lost its ability to protect
against DHT-dependent degeneration.
Using a quantitative rating score, we found
that PA led to a statistically significantmit-
igation of polyglutamine-expanded AR
degeneration, but this was lost in the dF-
OXO haploinsufficient flies (Fig. 5, bar
graph). Variation in the baseline (no PA
provided) level of neurodegeneration phe-
notype among the studied fly lines is likely
attributable to differences in the back-
ground genotype. These observations in-
dicate that PA confers protection against
mutant AR proteotoxicity in a FOXO-
dependent manner.
We developed a C. elegans model sys-
tem of neurodegeneration by combining a
nullmutation in the glutamate transporter
GLT-3 (glt-3) with a transgenic strain
[nuIs5 (Berger et al., 1998)] in which the
glr-1 promoter drives expression of an ac-
tivated form of Gs (abbreviated Gs*) and
GFP in glutamatergic neurons (Mano and Driscoll, 2009). The
glt-3; nuIs5 double mutants exhibit necrotic neuron death at all
stages of postembryonic development, with the strongest effect
seen in developmental stage L3. PA had a dose-dependent neu-
roprotective effect at the L3 stage, with complete rescue from
death using 10 nM PA (Fig. 6A). This concentration of PA had no
adverse effect on WT nematodes. We asked whether the effect of
PA is mediated by changing the timing of neurodegeneration or
by reducing it throughout development (Fig. 6B). To examine
this, we studied the effect of PA on the glt-3; nuIs5 double mu-
tants as a function of larval stage, and we found that neuronal
death was reduced in all developmental stages, with the strongest
effect observed in the developmental stages most prone to exci-
totoxicity. Neuron death was reduced in a statistically significant
manner in larval stages L2 (3.4 0.2 vs 2.5 0.2 dying neurons
per animals; n 44 vs n 49, vehicle vs PA; p 0.006) and L3
(4.2 0.2 vs 2.2 0.1 dying neurons per animals; n 63 vs n
65, vehicle vs PA; p 0.001) (Fig. 6B).
InC. elegans, stress resistance and longevity are promoted by a
reduction in the activity of insulin growth factor receptor (IGFR)
signaling pathway (i.e., hypomorphic alleles of IGFR, daf-2, and
PI3K, age-1), and this requires daf-16, the nematode homolog of
FOXO3a. This led us to wonder whether reducing activity in the
IGFR signaling pathway would alleviate nematode excitotoxicity.
To that end, we crossed theglt-3; nuIs5 double mutants with an
age-1mutant that carries the hx546 allele. This allele has a specific
anti-aging effect but does not affect development (Friedman and
Johnson, 1988). We generated triple-mutant nematodes (age-1;
glt-3; nuIs5) and found a robust neuroprotective effect of age-1
at larval stages L1–L3 (all p values0.001) (Fig. 6C).
Finally, although we showed that PA leads to accumulation of
FOXO3a in mammalian neuronal nuclei, we wanted to determine
whether the same was true in C. elegans. To this end, we studied
nematodes inwhich aDAF-16::GFP fusionproteinwas expressed in
body wall muscles. Addition of PA, but not vehicle, to the growth
substrate led to nuclear localization of the fusion protein and quan-
tification of the nucleus/cytoplasm ratio of DAF-16::GFP revealed a
statistically significant effect of PA (1.46 0.05 vs 3.44 0.55; n
36 vs n  27, vehicle vs PA; p  0.0001) (Fig. 6D). This result
indicates that PA has an evolutionarily conserved capacity to pro-
mote nuclear localization of the DAF16/FOXO3a transcription fac-
tor, and this is associated with resistance to necrotic neuron death.
Anothermethod for promotingnuclear localizationofDAF-16 (i.e.,
mutation of age-1) has a neuroprotective effect and further rein-
forces the notion that manipulation of the IGFR signaling pathway
could have promise as a neuroprotective strategy.
Discussion
Biochemical pathways that regulate longevity in yeast, C. elegans,
Drosophilamelanogaster, andmice also play a fundamental role in
Figure 6. PA treatment or reducing the activity of IGFR signaling pathway alleviates nematode excitotoxicity. A, PA has a
dose-dependent neuroprotective effect on nematode excitotoxicity:glt-3; nuIs5 double-mutant nematodes were cultured in
the presence of increasing concentrations of PA in the medium. The number of swollen, degenerating head neurons was scored
under Nomarski differential interference contrast optics in live animals at the L3 developmental stage. PA shows a statistically
significant, dose-dependent neuroprotective effect. B, The neuroprotective effect of PA is mediated by reducing the extent of
neurodegeneration throughout development. C, age-1(hx546 ), amutation that reduces IGFR signaling pathwaywithout altering
developmental decisions, protectsC. elegans fromexcitotoxicity. Degeneratingheadneuronswere scored in live animals as above.
D, PA causes preferential nuclear localization of DAF-16, the nematode homolog of FOXO3a. Animals express a transgene
(Pmyo-3:daf-16::gfp) that directs the expression of DAF-16::GFP fusion protein in body-wall muscle cells. In control animals (i.),
DAF-16::GFP is abundantly present in the cytoplasm. Animals grown in the presence of 10 nM PA (ii.) show preferential (although
not uniform) accumulation of DAF-16::GFP in the nucleus.
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resistance to stresses such as UV radiation, oxidative conditions,
heat shock, and misfolded and aggregation-prone proteins
(Finkel and Holbrook, 2000). Two transcription factors, heat-
shock factor 1 and DAF-16/FOXO3a, are essential mediators of
this longevity/stress resistance program in nematodes (Hsu et al.,
2003; Morley and Morimoto, 2004). Here we show that genetic
and pharmacological maneuvers that enhance nuclear localiza-
tion of FOXO3a protectmammalianmotor neurons in vitro from
four insults directly relevant to motor neuron diseases and abro-
gate neurodegeneration in two in vivo invertebrate model sys-
tems. The broad neuroprotective action of PA suggests that it acts
on a phylogenetically conserved, core stress resistance pathway.
Nuclear FOXO3a and PA can evoke a
neuroprotective program
We have used several complementary experimental platforms
(eachwith its own unique advantage) to investigate the biological
actions of PA. In summary, the experimental result suggest that
the neuroprotective actions of PA aremediated, at least in part, by
FOXO3a/DAF-16. First, in both rat neuron cultures and C. el-
egans, application of PA promotes nuclear accumulation of
FOXO3a or DAF-16. Second, PA evokes a dose-dependent in-
crease in FOXO-dependent transcription. Third, constitutive nu-
clear localization of FOXO3a mimics the neuroprotective action
of PA. Fourth, PA-mediated protection against mutant AR-
evoked degeneration is dFOXOdependent. Even without knowl-
edge of the direct molecular target of PA, this evidence favors the
view that PA acts, at least in part, in a FOXO3a transcription-
dependent manner.
During nuclear localization, members of the FOXO family of
transcription factors can control the expression of messages that
impact glucose metabolism, tumor suppression (through effects
on cell cycle progression and apoptotic responses), stress resis-
tance, and longevity (Ramaswamy et al., 2002; Greer and Brunet,
2005). The specific effects of FOXOs are both cell-type and con-
text dependent, and specific posttranslational modifications (i.e.,
phosphorylation, ubiquitination, acetylation) play a key role in
controlling the transcriptional readout (Brunet et al., 1999, 2004;
Hu et al., 2004; Berdichevsky et al., 2006). For example, work
from the Brunet laboratory has demonstrated that AMP-
activated protein kinase (AMPK) phosphorylates FOXO3a at six
sites, and the state of phosphorylation at these sites does not affect
nuclear localization (Greer et al., 2007a). Instead, these sites are
vital for expression of genes involved in oxidative stress manage-
ment and energymetabolism. Our finding that induction ofMn-
SOD by PA in cultures expressing mutant SOD parallels the ob-
servation of Greer et al. (2007b) that AMPK induction of sod-3
expression in nematodes is FOXO/DAF-16 dependent. Our pre-
liminary studies suggest that expression of mutant SOD with or
without PA does not influence the state of phosphorylation of
FOXO3a at AMPK sites S413 or S588 (our unpublished observa-
tions). Additional work is required to determine whether
FOXO3a undergoes posttranslational modifications in cells ex-
pressing mutant SOD, whether PA influences such a change, and
whether this has functional consequences.
It is noteworthy that expression of mutant SOD in neurons in
vivo, before neuron loss, is associatedwith an increase in FOXO3a
phosphorylation at T32 (one of the three key sites controlling
nuclear/cytoplasmic partitioning) and a reduction in the abun-
dance of MnSOD. These observations may indicate that, as a
consequence of expressing mutant SOD, neurons upregulate the
activity of FOXO3a kinases (and/or decrease the activity of
FOXO3a phosphatases), and this results in a reduction in the
expression of FOXO3a-regulated transcripts that combat proteo-
toxicity. In fact, there is a 2.5-fold increase in PI3K activity and
protein in spinal cords of ALS patients [the activator of the
FOXO3a kinases AKT and SGK (Wagey et al., 1998)] as well as a
3.6-fold increase in phosphor-AKT itself in mutant SOD mice
(Hu et al., 2003). These observations may indicate that a puta-
tively beneficial response to stress, such as increased expression
and activity of an antiapoptotic pathway, may have an unin-
tended adverse additional action on FOXO3a transcription.
Although we found that constitutive nuclear localization of
FOXO3a is neuroprotective, other groups obtained the opposite
result. Heterologous expression of TM FOXO3a led to death of
purified motor neurons and cerebellar granule neurons (Brunet
et al., 1999; Barthe´le´my et al., 2004) as well as PTEN-deficient
tumor cells (Nakamura et al., 2000). One factor thatmay contrib-
ute to these disparate observations is experimental platform. A
second contributory factor may be the level of transgene expres-
sion. It has been suggested that the level of nuclear FOXO3a
dictates the cellular readout (Nemoto and Finkel, 2002), and the
promoter in theHSV-based systemwe use generally evokesmod-
erate level of transgene expression (Neve et al., 1997).
Invertebrate models support PA acts via a
conserved mechanism
Given the potent neuroprotective activity of PA in vitro, we
sought to examine its effects in vivo. The two model systems we
chose have features that are reminiscent of humanmotor neuron
diseases. Neurons in the glt-3: nuIs5 nematode die an excito-
toxic cell death, and there is abundant evidence implicating exci-
totoxic mechanisms in ALS (Rao and Weiss, 2004). Spinobulbar
muscular atrophy is caused by expression of the proteotoxic
polyQ expanded AR, and transgenic expression of this mutant in
the fly eye similarly causes degeneration (Pandey et al., 2007). The
neuroprotective activity of PA in these model systems comple-
ments the in vitro studies with mammalian motor neurons. A
simple explanation for these observations is that PA operates on a
biochemical pathway common in all these experimental systems
that can overcome a diversity of noxious insults.
Extending these observations to the mutant SOD mouse
model of ALS at the present time is hindered by the lack of evi-
dence that PA can cross the blood–brain barrier. In preliminary
studies, we have not detected PA in brain homogenates after
intraperitoneal administration. Administration using an in-
trathecal catheter/osmotic minipump may be a viable option
(Storkebaum et al., 2005), although the long-term stability of
PA at body temperatures is not known. It may be possible to
synthesize derivatives of PA that retain the essential biological
activity and cross the blood–brain barrier (Georgiades and
Clardy, 2006).
Healthful aging and the FOXO3a signaling pathway
The onset of many neurodegenerative diseases in adulthood
raises the possibility that the causes of aging are specific contrib-
utors to disease pathogenesis. To the extent that this is true, ap-
plying our understanding of the molecular biology of longevity
may lead to new types of therapy for neurodegenerative diseases.
The present work on FOXO3a is an example of how manipula-
tion of a phylogenetically conserved, longevity-promoting sig-
naling pathway can effectively block neurodegeneration. This is
particularly interesting in light of a recent population-based
study of human longevity showing a strong association of
FOXO3a and healthy aging (Willcox et al., 2008). Agents that
Mojsilovic-Petrovic et al. • FOXO3a Signaling and Neurodegeneration J. Neurosci., June 24, 2009 • 29(25):8236–8247 • 8245
trigger neurodegenerationmay act in part by subverting the nor-
mally healthful actions of an aging pathway.
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